Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study.

ABSTRACT: Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib then nivolumab (CN) or nivolumab then cabozantinib (NC), is still unknown. The CABIR study aimed to identify the optimal sequence between CN and NC after frontline VEGFR-TKI. In this multicenter retrospective study, we collected data from mRCC pts receiving CN or NC, after frontline VEGFR-TKI. A propensity score (PrS) was calculated to manage bias selection, and sequence comparisons were carried out with a cox model on a matched sample 1:1. The primary endpoint was progression-free survival (PFS) from the start of second line to progression in third line (PFS_2-3 ). Key secondary endpoints included overall survival from second line (

SUBMITTER: Vano YA 

PROVIDER: S-EPMC9541795 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature